ADVENTRX Announces Launch Of New Corporate Website

Establishes Social Media Presence

News provided by

Dec 03, 2012, 08:30 ET

SAN DIEGO, Dec. 3, 2012 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced the launch of its redesigned and updated corporate website,www.adventrx.com. The new website features clinician videos, patient resources, and important news pertaining to sickle cell disease and ADVENTRX's lead product candidate, ANX-188 (purified poloxamer 188).

In addition, ADVENTRX has launched Facebook, Twitter and YouTube corporate pages to allow greater visibility with and access to information by the investment, medical and patient communities. Links to these social media sites can be found on the Company's website.

"We are hopeful that www.adventrx.com will become a valuable resource not only for our stockholders, but also for advocates, educators, caregivers, and the millions of people around the world who suffer from sickle cell disease. The ADVENTRX team is working to initiate a phase 3 clinical trial in patients with sickle cell disease and, once that trial begins, we will be the only company with a new chemical entity in phase 3 for the treatment of sickle cell disease. We believe this leadership position can serve as a platform for us to make a significant, positive impact in this important area," stated Brian M. Culley, Chief Executive Officer of ADVENTRX.

As is common for website transitions, there is a domain name system (DNS) propagation period during which internet service providers direct users to a new site. This propagation period typically is complete within 48 hours. Frequent or past visitors to www.adventrx.com may need to clear their web browser's cache to ensure they are viewing the updated corporate website.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical company developing proprietary product candidates to treat various diseases and conditions. The Company's lead product candidate, ANX-188, has potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function, which is compromised in a wide range of serious and life-threatening diseases and conditions. The Company initially is developing ANX-188 as a treatment for complications arising from sickle cell disease. More information can be found on the Company's website at www.adventrx.com.

Forward Looking Statements

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that are based on ADVENTRX's current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements regarding the value of ADVENTRX's new website to third party users, the timing of ADVENTRX's planned phase 3 study of ANX-188 and ADVENTRX's potential leadership position in development of therapies to treat sickle cell disease. Among the factors that could cause or contribute to material differences between ADVENTRX's actual results and those indicated from the forward-looking statements are risks and uncertainties inherent in ADVENTRX's business, including, but not limited to: the availability of and timeliness of updates to information in ADVENTRX's new website and the third party resources linked to therein; the potential for delays in the commencement or completion of ADVENTRX's planned clinical studies, including as a result of difficulties in completing manufacturing process development activities, manufacturing clinical trial material, meeting applicable regulatory requirements for clinical trial material, meeting applicable requirements of institutional review boards overseeing clinical study sites, or being subject to a "clinical hold"; the risk of suspension or termination of a clinical study, including due to lack of adequate funding or a "clinical hold"; ADVENTRX's reliance on contract research organizations (CROs) and other third parties to assist in the conduct of important aspects of its clinical studies, and that such third parties may fail to perform as expected; the risk that planned clinical studies are not successfully executed and/or do not successfully demonstrate the safety or efficacy of the investigational drug; the risk that, even if clinical studies are successful, the FDA determines they are not sufficient to support a new drug application; ADVENTRX's ability to obtain additional funding on a timely basis or on acceptable terms, or at all; the potential for ADVENTRX to delay, reduce or discontinue current and/or planned development activities, including clinical studies, partner its product candidates at inopportune times or pursue less expensive but higher-risk development paths if it is unable to raise sufficient additional capital as needed; the risk that the FDA does not grant marketing approval of ADVENTRX's product candidates, including ANX-188, on a timely basis, or at all; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at www.sec.gov.

You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date hereof, except as may be required by law.

(Logo: http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a)

SOURCE ADVENTRX Pharmaceuticals, Inc.